Literature DB >> 29433123

Endobronchial Treatment for Bronchial Carcinoid: Patient Selection and Predictors of Outcome.

Ellen M B P Reuling1,2, Chris Dickhoff1,3, Peter W Plaisier2, Veerle M H Coupé4, Albert H A Mazairac5, Rutger J Lely5, H Jaap Bonjer1, Johannes M A Daniels6.   

Abstract

BACKGROUND: Traditionally, surgical resection is the preferred treatment for typical carcinoids and atypical carcinoids located in the lungs. Recently however, several studies have shown excellent long-term outcome after endobronchial treatment of carcinoid tumors located in the central airways. This study investigates clinical and radiological features as predictors of successful endobronchial treatment in patients with a bronchial carcinoid tumor.
OBJECTIVES: To identify clinical and radiological features predictive of successful endobronchial treatment in patients with bronchial carcinoid.
METHODS: This analysis was performed in a cohort of patients with typical and atypical bronchial carcinoid referred for endobronchial treatment. Several patient characteristics, radiological features, and histological grade (typical or atypical carcinoid) were tested as predictors of successful endobronchial treatment.
RESULTS: One hundred and twenty-five patients with a diagnosis of bronchial carcinoid underwent endobronchial treatment. On multivariate analysis, a tumor diameter <15 mm (odds ratio 0.09; 95% confidence interval 0.02-0.5; p = <0.01) and purely intraluminal growth on computer tomography (CT scan) (odds ratio, 9.1; 95% confidence interval 1.8-45.8; p = <0.01) were predictive of radical endobronchial treatment. The success rate for intraluminal tumors with a diameter <20 mm was 72%.
CONCLUSIONS: Purely intraluminal disease and tumor diameter on CT scan seem to be independent predictors for successful endobronchial treatment in patients with bronchial carcinoid. Based on these data, patients with purely intraluminal carcinoid tumors with a diameter <20 mm on CT scan are good candidates for endobronchial treatment, regardless of histological grade. In contrast, all patients with a tumor diameter ≥20 mm should be directly referred for surgery.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Bronchial carcinoid; Bronchoscopy; Endobronchial treatment; Neuroendocrine tumor; Prognostic factors

Mesh:

Year:  2018        PMID: 29433123      PMCID: PMC6067647          DOI: 10.1159/000484984

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  33 in total

1.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

2.  Long-term outcomes and prognostic factors of patients with surgically treated pulmonary carcinoid: our institutional experience with 104 patients.

Authors:  Ertan Aydin; Ulku Yazici; Mahmut Gulgosteren; Yetkin Agackiran; Sadi Kaya; Erkmen Gulhan; Irfan Tastepe; Nurettin Karaoglanoglu
Journal:  Eur J Cardiothorac Surg       Date:  2011-02-01       Impact factor: 4.191

3.  The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.

Authors:  Craig E Daniels; Val J Lowe; Marie-Christine Aubry; Mark S Allen; James R Jett
Journal:  Chest       Date:  2007-01       Impact factor: 9.410

4.  Treatment and prognosis in bronchial carcinoids involving regional lymph nodes.

Authors:  N Martini; M B Zaman; M S Bains; M E Burt; P M McCormack; V W Rusch; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1994-01       Impact factor: 5.209

5.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

6.  Surgical treatment of bronchial carcinoid tumors: a single-center experience.

Authors:  Tiago Noguchi Machuca; Paulo Francisco Guerreiro Cardoso; Spencer Marcantonio Camargo; Leonardo Signori; Cristiano Feijó Andrade; Ana Luiza Schneider Moreira; José da Silva Moreira; José Carlos Felicetti; José Jesus Camargo
Journal:  Lung Cancer       Date:  2010-03-12       Impact factor: 5.705

7.  Long-term outcome after resection for bronchial carcinoid tumors.

Authors:  M K Ferguson; R J Landreneau; S R Hazelrigg; N K Altorki; K S Naunheim; J B Zwischenberger; M Kent; A P Yim
Journal:  Eur J Cardiothorac Surg       Date:  2000-08       Impact factor: 4.191

8.  Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.

Authors:  Arvind Kumar; Tarun Jindal; Roman Dutta; Rakesh Kumar
Journal:  Ann Nucl Med       Date:  2009-09-29       Impact factor: 2.668

9.  Long-term results after resection of bronchial carcinoid tumour: evaluation of survival and prognostic factors.

Authors:  Giulio Maurizi; Mohsen Ibrahim; Claudio Andreetti; Antonio D'Andrilli; Anna Maria Ciccone; Leda Marina Pomes; Cecilia Menna; Marianna Pellegrini; Federico Venuta; Erino Angelo Rendina
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-04-15

10.  68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.

Authors:  Valentina Ambrosini; Paolo Castellucci; Domenico Rubello; Cristina Nanni; Alessandra Musto; Vincenzo Allegri; Gian Carlo Montini; Sandro Mattioli; Gaia Grassetto; Adil Al-Nahhas; Roberto Franchi; Stefano Fanti
Journal:  Nucl Med Commun       Date:  2009-04       Impact factor: 1.690

View more
  7 in total

Review 1.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

Review 2.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

3.  Right middle lobe obstruction associated with synchronous endobronchial carcinoid and aspergillosis.

Authors:  Yoonjoo Kim; Dongil Park; Chaeuk Chung
Journal:  SAGE Open Med Case Rep       Date:  2021-04-12

Review 4.  Bronchial Carcinoids: From Molecular Background to Treatment Approach.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Javier Molina-Cerrillo; Nicolás Moreno Mata; Teresa Alonso-Gordoa
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

5.  A Multimodal Biomarker Predicts Dissemination of Bronchial Carcinoid.

Authors:  Ellen M B P Reuling; Dwayne D Naves; Pim C Kortman; Mark A M Broeckaert; Peter W Plaisier; Chris Dickhoff; Johannes M A Daniels; Teodora Radonic
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

6.  Multimodality multistaged management of large endobronchial carcinoid causing respiratory failure: A case report with review of literature.

Authors:  Abhijeet Singh; Sivaramakrishnan Mahadevan; Vallandramam R Pattabhiraman; Arjun Srinivasan
Journal:  Lung India       Date:  2018 Sep-Oct

7.  Bronchial carcinoid tumor managed with bronchial artery embolization before endobronchial resection: A case report.

Authors:  Shigehisa Kajikawa; Kojiro Suzuki; Nozomu Matsunaga; Natsuki Taniguchi; Toyonori Tsuzuki; Eisuke Fujishiro; Toshiyuki Yonezawa; Hiroyuki Tanaka; Toshio Kato; Akihito Kubo; Satoru Ito
Journal:  Thorac Cancer       Date:  2021-06-06       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.